Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 6 · below the Ichimoku cloud · RSI 39 · MACD below its signal · 6% above its 52-week low
| 5.07 | 52-week high | +457.14% |
| 1.56 | Previous month high | +71.43% |
| 1.43 | Previous week high | +57.14% |
| 1.08 | R3 (classic) | +18.32% |
| 1.02 | R2 (classic) | +12.45% |
| 0.9900 | Previous week low | +8.79% |
| 0.9700 | Previous day high | +6.59% |
| 0.9667 | R1 (classic) | +6.23% |
| 0.9600 | Previous month low | +5.49% |
| 0.9133 | Pivot | +0.37% |
| 0.9100 | Price now | |
| 0.8600 | Previous day low | −5.49% |
| 0.8600 | 52-week low | −5.49% |
| 0.8567 | S1 (classic) | −5.86% |
| 0.8033 | S2 (classic) | −11.72% |
| 0.7467 | S3 (classic) | −17.95% |
None of the 29 investors followed here reported a position in LSTA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LSTA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 8, 2026 | Brown Gregory BDirector | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 8, 2026 | Mazzo David JOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 81K | — |
| Jan 8, 2026 | Flowers Cynthia LouiseDirector | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 8, 2026 | Buck Kristen KOfficer | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jan 8, 2026 | Nisco JamesOfficer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jan 8, 2026 | Imam TariqGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jan 8, 2026 | Klosk Steven MarkDirector | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 8, 2026 | Azab MohammadDirector | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 8, 2026 | Henson HeidiDirector | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Jan 7, 2025 | Brown Gregory BDirector | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Jan 7, 2025 | Mazzo David JChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 81K | — |
| Jan 7, 2025 | Flowers Cynthia LouiseDirector | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Jan 7, 2025 | Buck Kristen KOfficer | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jan 7, 2025 | Nisco JamesOfficer and Treasurer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jan 7, 2025 | Klosk Steven MarkDirector | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Jan 7, 2025 | Azab MohammadDirector | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Jan 7, 2025 | Henson HeidiDirector | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 148.9 | -11.4 | 22.2 | -37.7 | 4.2 | 4.6 | -70.9 | 50.5 | -3.4 | -29.2 | -10.8 | −51.1% | |
| 2025 | -16.1 | -4.8 | -1.3 | 0.9 | 10.1 | 11.1 | -14.5 | -6.5 | 12.9 | 6.5 | -26.2 | -9.7 | −37.6% |
| 2024 | -9.5 | 18.6 | 6.5 | -12.5 | 7.7 | 18.0 | -7.2 | -11.8 | 5.6 | -5.7 | -2.5 | 8.0 | +9.2% |
| 2023 | 41.5 | -11.7 | 2.8 | 0.0 | 26.2 | -9.8 | -14.3 | -31.2 | -1.8 | 1.4 | 0.9 | 24.7 | +7.9% |
| 2022 | -8.3 | -9.1 | 2.9 | -29.2 | 0.0 | 3.9 | -5.7 | -2.0 | -37.0 | -8.4 | -17.5 | -27.7 | −79.9% |
| 2021 | 48.3 | -16.0 | 8.4 | -15.5 | -6.7 | 5.9 | -17.4 | -1.5 | -6.9 | -5.7 | -18.3 | -10.6 | −41.3% |
| 2020 | 15.9 | -11.7 | -30.0 | 13.3 | -6.9 | -6.3 | 27.5 | -14.5 | -7.2 | -16.1 | 0.7 | -5.9 | −43.0% |
| 2019 | 36.8 | -19.5 | -7.7 | -15.7 | -4.6 | -21.6 | 23.7 | -17.7 | 11.6 | -17.0 | 30.2 | -10.4 | −29.5% |
| 2018 | 21.9 | 11.4 | 22.4 | -28.6 | -4.6 | 62.6 | -22.6 | 5.2 | 12.0 | -20.8 | 6.9 | -28.7 | +1.4% |
| 2017 | 58.7 | 11.6 | 0.4 | -3.6 | -3.9 | -0.2 | -11.8 | -2.2 | -10.7 | -14.0 | 11.4 | 2.3 | +24.0% |
| 2016 | -49.1 | 5.5 | 29.3 | -8.0 | -21.7 | 9.3 | -6.1 | -12.6 | -4.1 | -11.4 | -9.0 | -24.3 | −73.8% |
| 2015 | -6.1 | 6.2 | -32.4 | 13.4 | -26.0 | -12.2 | -11.8 | -6.7 | -3.2 | -16.8 | -3.2 | -10.0 | −71.4% |
| 2014 | 6.5 | -3.6 | 0.7 | -16.0 | 15.0 | -4.3 | -5.4 | -6.8 | -3.8 | -7.2 | -23.2 | -4.3 | −44.7% |
| 2013 | 11.7 | -9.0 | 11.5 | -26.5 | 12.0 | 0.0 | 25.9 | 5.2 | 15.2 | -25.6 | 0.6 | 6.6 | +13.7% |
| 2012 | 23.5 | -9.5 | -33.3 | -5.3 | 16.7 | 16.7 | 51.0 | -16.2 | 11.3 | -7.2 | -1.6 | -4.8 | +17.6% |
| 2011 | 1.4 | -2.1 | 22.9 | 15.1 | -16.2 | -10.8 | -42.6 | -14.1 | -11.0 | 3.1 | -25.4 | 2.0 | −63.8% |
| 2010 | 16.1 | -21.1 | 26.8 | 35.0 | 15.2 | -34.6 | 4.4 | -17.3 | 28.5 | -7.4 | -30.9 | 8.5 | −9.0% |
| 2009 | 78.7 | -16.7 | 38.6 | 0.0 | 120.6 | -11.2 | -7.9 | 8.0 | -0.5 | 1.1 | -9.5 | -9.9 | +229.8% |
| 2008 | 24.6 | -1.2 | -10.3 | -10.1 | -24.1 | -2.0 | -4.0 | 10.5 | -4.8 | 13.0 | -20.4 | -47.8 | −64.9% |
| 2007 | -28.0 | -25.9 | 32.5 | -26.4 | 10.3 | 23.3 | -5.7 | 0.0 | -6.0 | -27.0 | -39.1 | -35.9 | −82.1% |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
No analyst coverage for this instrument.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.